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Background: This study aimed to investigate the prevalence and clinical relevance of chronic cerebrospinal venous
insufficiency (CCSVI) in multiple sclerosis (MS) patients and healthy controls using extra- and intracranial colour
Doppler sonography.
Methods: We examined 146 MS patients, presenting with a clinically isolated syndrome, relapsing-remitting,
secondary progressive, or primary progressive MS, and 38 healthy controls. Sonographic examination was
performed according to Zamboni’s protocol and was performed by three independent sonographers. The results of
sonographic examination were compared with clinical and demographic characteristics of the patients.
Results: CCSVI, defined as the presence of at least two positive Zamboni’s criteria, was found in 76% of MS patients
and 16% of control subjects. B-mode anomalies of internal jugular veins, such as stenosis, malformed valves, annuli,
and septa were the most common lesions detected in MS patients (80.8%) and controls (47.4%). We observed a
positive correlation between sonographic diagnosis of CCSVI and the patients’ age (p = 0.003). However, such a
correlation was not found in controls (p = 0.635). Notably, no significant correlations were found between
sonographic signs of CCSVI and clinical characteristics of MS, except for absent flow in the jugular veins, which was
found more often in primary (p<0.005) and secondary (p<0.05) progressive patients compared with non-progressive
patients. Absent flow in jugular veins was significantly correlated with patients’ age (p < 0.0001).
Conclusions: Sonographically defined CCSVI is common in MS patients. However, CCSVI appears to be primarily
associated with the patient’s age, and poorly correlated with the clinical course of the disease.
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Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system (CNS) characterized by inflamma-
tion, demyelination, and neurodegeneration [1]. However,
neuropathological studies have underlined the presence of
a subset of patients with a pattern that closely mimics
tissue alterations found in the early stages of white matter
ischemia [2]. Moreover, cerebral perfusion studies have* Correspondence: raffaele.liuzzi@cnr.it
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reproduction in any medium, provided the orshown diffuse hypoperfusion in patients with MS com-
pared with age-matched controls with a greater cerebral
blood flow decrease in primary progressive (PP) MS com-
pared with relapsing-remitting (RR) MS [3]. Recently, a
strong correlation between MS and a vascular condition
called chronic cerebrospinal venous insufficiency was
reported [4].
Chronic cerebrospinal venous insufficiency (CCSVI) is
characterized by anomalies of the main extracranial cere-
brospinal venous routes. CCSVI is detected by selective
venography [4-10] and extracranial venous echo-colour
Doppler (ECD) [4,9-12] with higher sensitivity and specifi-
city than magnetic resonance venography (MRV) [9]. The
prevalence of CCSVI in MS patients is highly variableLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prevalence of CCSVI in patients with MS, those with
clinically isolated syndrome (CIS), those with other neuro-
logical diseases, and healthy controls (HCs), using echo-
color Doppler (ECD), showed an increased prevalence of
CCSVI in MS [14]. This finding suggests that CCSVI does
not have a primary causative role in the development of
MS. However, perfusion studies have shown a decrease in
cerebral perfusion in MS subjects and HCs with CCSVI
[15,16].
To date, there are only few studies regarding the relation-
ship between venous abnormalities, phenotype, and the
clinical course of MS [17-19], with different and sometimes
conflicting results.
This study aimed to investigate the prevalence of CCSVI
in a representative MS population and HCs using ECD.
We also investigated the clinical relevance and correla-
tions of CCSVI with MS disease parameters.
Methods
Patients
This single-centre, cross-sectional study included 171 con-
secutive MS patients and 41 sex- and age-matched HCs.
Inclusion criteria were diagnosis of MS, according to the
McDonald criteria [20], including RR, secondary progres-
sive (SP) MS, and PPMS, as defined by Lublin [21], and
diagnosis of CIS. The HC group included relatives of MS
patients and healthy volunteers. For all patients, exclusion
criteria were the presence of relapse and steroid treatment
in the 30 days preceding study entry and, for HCs, a his-
tory of cerebral congenital vascular malformations and
pre-existing medical conditions known to be associated
with brain pathology (e.g., cerebrovascular disease and a
positive history of alcohol abuse).
Study assessments
All of the participants underwent a clinical examination
and intra- and extracranial ECD of the neck in the same
week. Biochemistry was performed to exclude haema-
tological or other medical conditions that could affect
haemorheology. Standard demographic and clinical infor-
mation on all participating subjects were acquired. This
included, but was not limited to age, sex, familial history,
detailed medical history of vascular risks with particular
emphasis on venous diseases, age at disease onset, age at
diagnosis, time interval between first and second relapses,
annualized relapse rate, and current and previous therapy
information. Disease onset symptoms were retrospectively
recorded and classified into five categories according to
the Expanded Disability Status Scale (EDSS) functional
system involved: visual, pyramidal, sensory, subtentorial
(cerebellar and brain-stem), and spinal symptoms. Actual
disease phenotype was also assessed and divided into the
same five categories, according to the most disabledfunctional system at the time of evaluation. A physical
examination was performed with measurement of blood
pressure, and EDSS [22] and single EDSS functional
systems scores, and Multiple Sclerosis Severity Scale
(MSSS) [23] scores were calculated, and disease subtype
was classified.
Standard protocol approvals, registrations, and patient
consents
This study was approved by the “Carlo Romano” ethics
committee of the Federico II University of Naples, and
informed consent was obtained from all subjects.
Colour Doppler sonography evaluation
Colour Doppler sonography was performed by the same
radiologist (MM with greater than 20 years of vascular
ultrasound experience) with the iU22 Ultrasound System
(Philips, Amsterdam, The Netherlands) equipped with a
3.0–9.0 MHz linear wide-band transducer, a 5.0–8.0 MHz
microconvex probe, and a 1.0–5.0 MHz phased array
transcranial probe.
Intracranial and extracranial venous outflow were evalu-
ated according to the Zamboni criteria, based on the detec-
tion of five criteria as previously described [4]. A subject
was considered CCSVI-positive if two or more Zamboni
criteria were fulfilled. The radiologist that performed ECD
was not blinded to the disease status of patients.
The images were stored and anonymously coded with
an identification number. A further evaluation was per-
formed off-line and independently repeated twice by two
blinded radiologists (OD, VM) who reviewed all the
images. The CCSVI diagnosis was considered valid only if
the findings of the three radiologists agreed for each single
criterion.
Statistical analysis
Continuous data are reported as mean and standard
deviation or median and range, and categorical data as
percentages. For descriptive statistics and estimates of
prevalence, the t-test, the U test (Mann–Whitney), Fisher’s
exact test, and the χ2 test were used. Despite the fact that
diagnosis of MS is not a gold standard test to diagnose
CCSVI, sensitivity, specificity, and relative odds ratios
(ORs) between HCs and patients with MS were calculated,
using direct computation from 2 × 2 tables, to obtain
results easily comparable with previous studies [4,14].
Prevalence rates for each of the five Zamboni criteria, as
well as for different CCSVI presence groups, were calcu-
lated. Residual analysis was performed to assess diffe-
rences in the distribution of these venous criteria among
MS subtypes. Logistic regression techniques were used to
evaluate correlations between CCSVI presence and clinical
parameters. Significance was denoted when p was <0.05
Lanzillo et al. BMC Neurology 2013, 13:20 Page 3 of 7
http://www.biomedcentral.com/1471-2377/13/20by using two-tailed tests. Statistical analyses were per-
formed using SPSS (version 18.0 Chicago, IL).
Results
Demographic and clinical data of MS patients and control
groups are shown in Table 1. Significant differences in age,
EDSS, and disease duration were evident in the subgroups.
MS patients belonged to four clinical subtypes (53 RR,
58 SP, 19 PP, and 16 CIS), and were treated in 70% of cases
with various therapies (59 with interferon beta-1, 30 with
natalizumab, 8 with glatiramer acetate, 3 with fingolimod,
1 with azathioprine, and 1 with mitoxantrone). Of the
remaining 44 untreated patients, eight were naïve to any
disease modifying therapy, while the others had been pre-
viously treated with one or more different drugs.
It was not possible to assess all 5 Zamboni criteria for
the absence of an adequate temporal window or for image
artefacts that had not allowed full exploration of the jugu-
lar valve plane in nine patients (5%). Concordance among
the three ultrasonographers on the presence or absence of
CCSVI was found in 146/171 (85.4%) MS patients and
38/41 (92.7%) HCs who were included in the statistical
analysis.
One hundred and eleven MS patients (76%) and six
HCs (16%) were considered as CCSVI-positive (Figure 1,
p<0.001). The sensitivity and specificity of the presence of
CCSVI for MS were 76% (95% CI 68.6–82.4) and 84%
(95% CI 78.3–93.1), respectively, with an OR of 16.9 (95%
CI 6.5–43.8) (Table 2). The prevalence of one or more
positive Zamboni criteria was higher in the MS group than
in the HC group (93.2% vs 63.2%, p<0.001). For three ful-
filled criteria, the prevalence was significantly higher in the
MS group (32.2%) than in the HC group (7.9%, p<0.003).Table 1 Demographic and clinical characteristics of HCs, all M
HCs (38) All MS (146) P value C
Age (y) 37±10 40±9 0.112
mean (±SD)
M/F 18/20 49/97 0.115
EDSS 4
median (range) (1.5-7.0) (
MSSS 5.3
median (range) (1.2-9.5) (
Disease duration (y) 11
median (range) (0–35)
Onset age (y) 28.0
median (range) (13.0-57.0) (1
aAge, EDSS, and disease duration were significantly higher in PPMS and SPMS patie
bMale sex was significantly prevalent in PP patients.
cOnset age was significantly higher in PPMS patients than in RR and SP patients.
Abbreviations: CIS: clinically isolated syndrome; HCs: healthy controls; MS: multiple s
multiple sclerosis; SPMS: secondary progressive multiple sclerosis.The prevalence of five single venous criteria is shown in
Figure 1. B-mode abnormalities of the internal jugular vein
(IJV) presenting as stenosis, malformed valves, annulus,
and septa (criterion 3), were the most frequently detected
anomalies in MS patients (80.8%) and HCs (47.4%), fol-
lowed by reflux in the jugular or vertebral vein (criterion 1)
(63.0% in MS and 21.1% in HCs).
CCSVI was equally distributed in the different MS
subtypes (χ2= 0.583, p=0.90), while the absence of de-
tectable flow in the IJV or in the vertebral vein (VV)
(criterion 4) was significantly less frequent in the non-
progressive forms compared with the progressive forms
of the disease (11.3% in RR and 6.3% in CIS patients, vs
57.9% in PP, p<0.005; and vs 36.2% in SP, p<0.05)
(Figure 1). The presence of CCSVI was positively related
to age in the whole sample (p=0.001) and in the MS
group (p=0.003), but not in HCs (p=0.635). No correla-
tions were found between the presence of CCSVI and
sex or clinical parameters, such as age at onset, EDSS,
MSSS score, disease duration, number of total relapses,
relapses in the last 2 years, and mostly impaired EDSS
functional system. Onset symptoms were found in
132 patients (90.4%). No difference in the prevalence of
CCSVI was found in relation to disease onset symptoms.
Therapy parameters (number of subsequent disease-
modifying therapies to which patients had been exposed
and the total time of therapy exposure) were not related
to the presence of CCSVI.
Single venous criterion 1, 3, and 4 positivity was related
to age in SM patients (p=0.029, 0.012, and 0.0001, respec-
tively). In particular, criterion 1 was strongly related to age
in RR patients (p=0.006) and criteria 4 in PP patients
(p=0.01)S patients, and MS subtypes
Disease group (n)
IS (16) PPMS (19) RRMS (53) SPMS (58) P value
32±7 48±11 37±9 43±7 0.001a
6/10 6/13 13/40 17/41 0.001b
2.3 5.5 3.0 5.0 0.001a
1.5-3.5) (3.5-7.0) (2.0-5.0) (2.5-7.0)
6.3 5.3 5.4 4.9 0.122
2.1-8.6) (3.7-9.1) (1.5-8.6) (1.6-9.4)
1 13 7 16 0.001a
(0–11) (4–24) (1–29) (3–35)
29.3 35.0 27.6 27.0 0.036c
8.5-41.0) (18–57) (15–46) (13–44)
nts than in CIS and RRMS patients.


















No Flow IJV/VV Negative CSA CCSVI
spMS 55,5% 25,9% 86,2% 36,2% 6,9% 79,3%
rrMS 71,7% 32,1% 73,6% 11,3% 7,5% 73,6%
ppMS 57,9% 36,8% 78,9% 57,9% 5,3% 73,7%
CIS 68,8% 12,5% 87,5% 6,3% 0,1% 75,0%
MS tot. 63,0% 28,1% 80,8% 26,7% 6,2% 76,0%




Figure 1 Prevalence rates of Zamboni criteria and CCSVI for disease group (HC, MS) and MS subtype. aThe prevalence of CCSVI was
significantly higher in the MS group than in the HC group (p<0.001). bThe absence of IJV and/or VV flow (Cr 4) was significantly more frequent in
the PPMS form of disease compared with the RRMS form (p<0.005). cB-mode anomalies were the most frequently detected anomalies in MS
patients and HCs. Abbreviations: CIS: clinically isolated syndrome; CCSVI: chronic cerebrospinal venous insufficiency; HCs: healthy controls; MS:
multiple sclerosis; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-remittent multiple sclerosis; SPMS: secondary progressive multiple
sclerosis; Cr: Echo-Doppler criterion.
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We assessed the presence of CCSVI in MS patients and
HCs, with a high interrater concordance (85.4% and 92.7%,
respectively). Our study showed a higher prevalence of
CCSVI in MS patients and a relatively higher specificity of
CCSVI for MS, with a high OR for the diagnosis of MS vs
HCs. The presence of CCSVI was strongly related to age in
the whole sample and in MS patients, without any other
clinical correlation. Single venous criteria were also related
to age, and the absence of detectable flow in the IJV and/or
VV (criterion 4) was more prevalent in PPMS patients
compared with the other forms of MS, and was also related
to age.
Our results are consistent with other studies that
reported an increased prevalence of CCSVI in MS, despiteour finding that sensitivity and specificity were lower than
previously reported values [4,9,10]. Our finding of a higher
prevalence of criterion 4 in PPMS (58%) is also consistent
with other studies that showed significantly more MR
venography abnormalities in PP patients [24], as well as a
longer cerebral circulation time in patients with progres-
sive MS compared with nonprogressive MS [25,26],
suggesting a role of hypoperfusion in neurodegeneration.
We did not find any relation of CCSVI with any clinical
or demographic parameters, apart from age. These results
do not indicate that CCSVI has a primary causative role in
MS, as recently suggested in a recent review [27]. More-
over, a strong correlation between CCSVI and age, espe-
cially in MS patients, does not favour the hypothesis of the
congenital nature of neck vascular alterations. The absence
Table 2 Sensitivity, specificity, and odds ratios of single colour Doppler sonography criteria in MS patients and HCs
Sensitivity, % (95% CI) Specificity, % (95% CI) Odds ratio, (95% CI)
Reflux of the IJV and/or VV (Cr 1) 63,0 78,9 6,4
(55,0-70,5) (64,2-89,5) (2,7-14,9)
Intracranial reflux (Cr 2) 28,1 84,2 2,1
(21,3-35,8) (70,3-93,1) (0,8-5,4)
IJV stenosis B-mode anomalies (Cr 3) 80,8 52,6 4,7
(73,9-86,6) (37,1-67,8) (2,2-10,0)
No flow in the IJV and/or VV (Cr 4) 26,7 97,4 13,5
(20,0-34,3) (88,4-99,6) (1,8-101,6)
Negative CSA (Cr 5) 6,2 97,4 2,4
(3,1-10,9) (88,4-99,6) (0,3-19,8)
CCSVI 76,0 84,2 16,9
(68,6-82,4) (70,3-93,1) (6,5-43,8)
An odds ratio greater than 1.0 indicates an increased likelihood of a diagnosis of CCSVI in MS patients versus controls.
Abbreviations: MS: multiple sclerosis; HCs: healthy controls; CCSVI: chronic cerebrospinal venous insufficiency; Cr: criterion; IJV: internal jugular vein; VV: vertebral
vein; CSA: cross sectional area; CI: confidence interval.
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of the small number of subjects in this group (power=30%).
Haemodynamic alterations in neck veins, such as jugular
reflux in elderly people, have been described, and interes-
tingly, they are associated with infratentorial white matter
hyperintensity [28].
With regard to our finding of the correlation of criterion
4 with progressive forms of disease, the absence of flow in
the IJV and/or VV could be related to factors that deter-
mine extrinsic compression of neck veins. The IJV passes
below the sternocleidomastoid muscle to join the sub-
clavian vein. Therefore, contraction of neck muscles or
rotation of the head may result in a compression of these
veins with a significant reduction in blood flow, even
approaching complete occlusion [29]. The relation be-
tween vein biomechanics, surrounding muscle tone and
trophism, and the fascial envelope has been demonstrated
in the leg [30,31], but not in the IJVs. Moreover, in our
study, the examiner paid attention to the inclination of the
patient’s head and used an appropriate neck support to
avoid hyperextension or rotation of the head. However, it
is not possible to exclude with certainty the influence of
neck muscles on venous haemodynamics, especially in
patients with higher neurological disability. In the current
study, progressive patients were older than nonprogressive
patients, and criterion 4, similar to criteria 1 and 3, was
related to age, confirming that this appears to strongly
influence venous hemodynamic alterations in MS. Indeed,
PP and SP patients who showed a similar mean age had a
comparable prevalence of criterion 4 (p=0.053).
However, it remains unknown if CCSVI is a causal
factor or a consequence of MS. Our findings suggest that
CCSVI may be a secondary effect rather than a cause of
MS, and they indicate that in MS patients, venous valvesbecome less continent with ageing, in association with
morphological and functional changes. Many reports have
shown the presence of ageing-related increased fibrosis
and thickening of the valve leaflets and vein wall [32-36],
and decreased compliance of the vein wall [37-39].
Changes in compliance in the vein wall affect venous
blood flow, and thickened, stiff leaflets disrupt normal
blood flow during the valvular cycle. Several studies have
reported hypoperfusion of brain parenchyma in patients
with MS, advancing with disease progression [40-43], and
it is possible that neck venous anomalies develop second-
arily to reduced perfusion. The combination of chronic
hypoxia or intermittent hypoxia and haemodynamic fac-
tors creates conditions that convert the endothelium of
veins to a proinflammatory and procoagulant phenotype
[37], which is characterized by the production of plas-
minogen activator inhibitor-1, release of von Willebrand
factor, exposure of P-selectin, secretion of the vasocon-
strictor endothelin-1, and production and release of reac-
tive oxygen species. Moreover, hemodynamic forces are
important modulators of vascular structure. In rabbits,
progressive intimal thickening occurs when shear stress is
reduced to subnormal levels with preserved endothelium
[44]. There is no evidence of inflammatory infiltrates in
neck vein walls in MS [26]. In MS patients, vein walls
appear to undergo remodelling of collagen fibres, altering
the collagen I/III proportion [26]. The presence of colla-
gen alterations might be due to age-related changes in the
vein wall and valves, which have been described in renal
veins [33]. In our study, changes corresponding to those
found in normal ageing of veins were found in MS patients,
and interestingly, this phenomenon was more evident in
progressive MS forms where changes in the vein wall and
valves caused the most serious hemodynamic consequences.
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suggesting that a neurological process could play a role
in CCSVI progression through vasoactive substances
(e.g., endothelin-1) or proinflammatory agents, which could
act on previously susceptible segments of blood vessels
(i.e., malformed vein valves) [45]. This hypothesis would
explain the higher prevalence of CCSVI in MS patients and
its relation to patients’ age. The same article also suggested
a parallel between venous and aortic valves stenosis, which
are different entities, but probably share common features.
MS patient live in a state of venous stasis that can be attri-
buted to excessive ageing of veins and venules secondary to
three elements: 1) chronic inflammation that induces
changes in structure and function of the vein wall (in par-
ticular, the endothelium); 2) MS-associated alteration in
blood flow; and 3) a shift to a hypercoagulable state [46,47].
These changes are located in the trunk wall and the lesions
are non-homogeneous and dispersed. The development of
new and modern biomedical imaging techniques would be
useful for investigating venous valvular pathophysiology in
animal models and human subjects.
Conclusions
In conclusion, our results suggest a higher prevalence of
CCSVI in MS patients, which increases with age, possibly
more precociously in MS patients than in healthy people,
but without any correlation with disability and disease pro-
gression. Normal “ageing” of neck veins should be investi-
gated and it should be verified whether reduced cerebral
blood flow and cerebral venular chronic inflammatory
exposure, both evident in MS, induce venous brain outflow
alterations. We believe that to determine the relationship
between CCSVI and MS, a more sophisticated assessment
is necessary, especially at the beginning of disease and with
a longitudinal prospective.
In particular, more refined and quantitative measures,
such as blood flow velocity, volume flow, and cerebral
circulation times, could be more reliable in assessing the
physiological relevance of venous outflow abnormalities.
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